Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618463 | 0.77 | GAA (0.40) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL13450933 | 0.67 | GAA (0.40) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL7062448 | 0.67 | MGAM (0.40) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL25244259 | 0.66 | MGAM (0.39) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL16710262 | 0.66 | GAA (0.39) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL24784617 | 0.65 | MGAM (0.38) | GAAMGAMSIMGAM2POLB | |
| Hydrochloric Acid SCHEMBL21496927 | 0.64 | MGAM (0.36) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL23824765 | 0.62 | ALDH1A1 (0.36) | GAAMGAMSIMGAM2POLB | |
| SCHEMBL3705538 | 0.62 | MGAM (0.39) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL3705541 | 0.62 | MGAM (0.39) | GAAMGAMSIMGAM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019398-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6440974-B2 | ANTITUMOR AGENTS | SCHERING CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20010014681-A1 | Compounds useful for inhibition of farnesyl protein transferase | DOLL RONALD J (US) | 2001-08-16 | — | — | US | disclosed |
| US-6228865-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES AS ANTITUMOR AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2001-05-08 | — | — | US | disclosed |
| EP-1019398-A1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998057968-A1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014681-A1 | Compounds useful for inhibition of farnesyl protein transferase | FNTB, FNTA, HCCS | GAA 2865/4885MGAM 3987/4885SI 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.